960 x 350_41

Next Generation Sequencing Services

Global Next Generation Sequencing (NGS) Services

With 4 global laboratory locations, Q2 Solutions offers a range of next generation sequencing services to support drug discovery, precision medicine, and clinical development. We offer expertise in assay design, development, and validation, plus a translational genomics team comprised of both assay development and bioinformatic scientists, who lead the industry in high complexity testing and analysis. Q2 Solutions offers the following next generation sequencing services:

Service Capability
Exome Sequencing
  • Low input procedure optimized for intact and FFPE material
  • Flexible hybridization method that allows for use of various standard and customized ROI probe sets
RNA Sequencing Capabilities include:
  • Library preparation from both intact and degraded RNA from FFPE, blood, tissue, and cells
Techniques include:
  • Hybridization-based method targeting the human transcriptome
  • Poly-A selection method for intact material
  • Ribosomal RNA depletion method for degraded and non-coding RNA
Whole Genome Sequencing Optimized method for FFPE and intact material, using low input and minimal amplification
DNA and RNA Isolations DNA and RNA extraction capabilities from a large spectrum of original material, including FFPE, blood, tissue, and cells
HTG Edge Seq Panels
  • HTG EdgeSeq library preparation and Illumina Sequencing
  • Low sample input, no RNA isolation required
  • 3500+ targets in a single reaction
ThermoFisher ion Torrent AmpliSeq and Oncoming Panels
  • Library preparation and Ion Torrent S5 XL or PGM Dx sequencing
  • DNA, RNA, or simultaneous profiling available
  • Customizable
  • Whole Transcriptome panel available
NanoString nCounter Panels
  • Probe Hybridization based capture, RNA copies counted by nCounter
  • No amplification required
  • Customizable
  • Up to 800 targets in a single reaction
Bioinformatics
  • Alignment, gene/isoform/junction counts, QC, bacterial/viral detection
  • Gene fusion detection
  • Variant calling
  • HLA allele calling
  • Group comparisons and clinical biostatistics
  • On-site support

Related Thought Leaders Insights


Risk Management for Biotech Companies in Clinical Trials

  In this episode, the second of a three-part series, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Alan Wookey, Global Head of Companion Diagnostics discuss how to manage...

Bridging the Ligand Binding Assays and LC-MS Disciplines for Hybrid Assays

Assessing the pharmacokinetics of biologics presents several analytical challenges, from the use of critical reagents and assay sensitivity requirements to regulatory and throughput considerations....

Characterization of SARS-CoV-2 using the Ion AmpliSeq SARS-CoV-2 research panel

The Thermo Fisher Ion AmpliSeq SARS-CoV-2 Research Panel is a targeted NGS solution that facilitates sequence analysis of the SARS-CoV-2 genome. This assay’s performance and the Pangolin lineage...